Raf-1 is a serine-threonine protein kinase that functions as a central component of the mitogen-activated protein kinase signal transduction pathway. Raf-1 activity is currently assayed in vitro by either measuring 32 P incorporation into MEK, Raf-1's only characterized substrate, or by using the phosphorylated MEK to initiate a coupled assay culminating in the phosphorylation of myelin basic protein by MAP kinase. These assays are plagued by a potential lack of speci®city in the case of the former, and the time consuming and error-prone nature of the later indirect assay. In this report, we demonstrate a novel single step assay for Raf-1 kinase activity based on phosphorylation of recombinant MEK-1, detected using an activation-speci®c MEK antibody that recognizes MEK only when speci®cally phosphorylated by Raf-1 on Ser 217 and Ser 221. The assay readily detected stem cell factor-mediated Raf-1 activation. MEK phosphorylation by immunoprecipitated Raf-1 plateaued at 10 min following initiation of the kinase reaction and was completely dependent on the inclusion of Raf-1. There was a linear correlation between the degree of MEK phosphorylation and the amount of Raf-1 protein immunoprecipitated. In addition to detecting growth factor-mediated activation, the assay was also able to detect paclitaxel-mediated Raf-1 activation. This assay is rapid, sensitive, and speci®c and therefore is a marked improvement over currently utilized techniques. Oncogene (2000) 19, 5030 ± 5033.
Introduction
The c-raf gene was ®rst identi®ed as the normal cellular counterpart of v-raf, the transforming gene of murine sarcoma virus 3611 (Rapp et al., 1983) . The protooncogene product of c-raf (Raf-1) is a serine-threonine protein kinase that functions in protein kinase cascades important for mitogenic signaling (Avruch et al., 1994) . Raf-1 phosphorylates and activates mitogen-activated protein (MAP) kinase kinase (MKK, also known as MEK), the speci®c activator of MAP kinase. MAP kinase in turn phosphorylates several regulatory proteins in the cytoplasm and nucleus to alter the program of transcription and translation required for mitogenesis (for reviews see Robinson and Cobb, 1997; Lewis et al., 1998) .
Raf-1 regulation is a complex process that integrates information from multiple signaling pathways. Loading of Ras with GTP, catalysed by Ras guanine nucleotide exchange factors, including mammalian son-of-sevenless (Sos), induces the binding of Raf-1 to Ras and the subsequent translocation of Raf-1 to the plasma membrane (Vojtek et al., 1993; Marias et al., 1995) . This translocation is accompanied by an enhancement of the basal kinase activity of Raf-1. The Raf-1 kinase is further activated at the membrane by changes in inter-and intramolecular interactions and phosphorylation events (Fabian et al., 1993; Jelinek et al., 1996; Lou et al., 1997; Roy et al., 1997) . To date, MEK is the only physiological substrate of Raf-1 (Kyriakis et al., 1992) . Binding of MEK to the C-terminal end of activated Raf-1 results in the phosphorylation and subsequent activation of MEK (Dent et al., 1992; Van Aelst et al., 1993) . Using a combination of phosphopeptide sequencing and mutagenesis, it has been demonstrated both in vivo and in vitro that Ser 217 and Ser 221 within the catalytic domain of rabbit MEK (Ser 218 and 222 of human MEK) are the sites of phosphorylation that result in its activation (Alessi et al., 1994; Cowley et al., 1994, Zheng and Guan, 1994) .
The kinase activity of Raf-1 is conventionally assayed in vitro in a kinase cascade reaction initiated by an immunocomplex containing Raf-1. The immunocomplex catalyses activation of recombinant MEK, which can activate recombinant MAP kinase. MAP kinase activity is determined by the phosphorylation of a speci®c substrate, myelin basic protein (MBP) in the presence of [g 32 P]ATP (Alessi et al., 1995) . A second approach to assessing Raf-1 activation uses recombinant MEK as a direct substrate for Raf-1 phosphorylation in the presence of [g 32 P]ATP (Fabian et al., 1993; Kyriakis et al., 1993) . The inherent problem in the coupled assay lies in the fact that it is a time consuming multistep process subject to errors at each step. While the second approach may eliminate some of the problems associated with a multistep assay, immunoprecipitated Raf-1 is assayed by measurement of total phosphorylation of MEK. Phosphorylation can occur at sites not involved in MEK activation by kinases other than Raf-1 that may contaminate the immunoprecipitate. One such potential contaminant is MAP kinase, which phosphorylates MEK on Thr 286 and Thr 292 (Brunet et al., 1994; Saito et al., 1994; Alessi et al., 1995) . In this report, we demonstrate a single step assay for Raf-1 kinase activity based on MEK phosphorylation detected using an activation-speci®c MEK antibody that recognizes MEK when speci®cally phosphorylated at Ser 217 and Ser 221 by Raf-1.
Results and Discussion
Growth factors which initiate signaling through the MAP kinase pathway include stem cell factor (SCF), which activates the Kit receptor tyrosine kinase (Okuda et al., 1992) . To investigate the eectiveness of this assay in detecting growth factor-mediated Raf-1 activation, we utilized the H526 small cell lung cancer (SCLC) cell line which expresses Kit and responds to recombinant SCF with MAP kinase activation and mitogenesis (Krystal et al., 1998) . After SCF stimulation of serum-starved H526 cells, Raf-1 was immunoprecipitated and its ability to phosphorylate recombinant MEK-1 was assessed using increasing incubation intervals to determine the optimum incubation time. The samples were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) and the blot probed with the phospho-MEK antibody which recognizes MEK when phosphorylated by Raf-1 at Ser 217 and Ser 221. Figure 1a illustrates that MEK phosphorylation peaked by 10 min and was sustained thereafter for the reminder of the 30-min incubation time.
To determine the optimum recombinant MEK-1 substrate concentration for this assay, H526 cells were stimulated with SCF or left untreated and Raf-1 was immunoprecipitated using a polyclonal antibody directed against the carboxy-terminus. Increasing amounts of recombinant MEK-1 substrate were used in the kinase reaction. Figure 1b indicates that the assay was able to dierentiate between inactive and active Raf-1 isolated from untreated and SCF-treated cells respectively, with increasing sensitivity at higher substrate concentration. The optimum MEK substrate amount for 500 mg of cellular protein lysate was found to be between 400 and 500 ng. No MEK phosphorylation was detected when non-immune sheep serum was used for the immunoprecipitation step.
To determine if there was a correlation between the amount of input Raf-1 protein and kinase activity judged by the degree of phosphorylation of MEK, H526 cells were stimulated with SCF and increasing amounts of protein lysate were used in the Raf-1 immunoprecipitation. A kinase assay was then performed on the Raf-1 immunocomplex using a constant amount of recombinant MEK-1 substrate. The results in Figure 2A indicate there was a correlation between the amount of Raf-1 protein immunoprecipitated and the degree of MEK phosphorylation, which reached a plateau between 800 and 1600 mg of protein lysate. The saturation above 800 mg appeared to be due to a limiting amount of substrate at high Raf-1 concentration. Two-dimensional densitometric analyses of the phospho-MEK and Raf-1 bands in Figure 2b indicate there was a linear correlation between the degree of MEK phosphorylation and the amount of input Raf-1 protein up to 800 mg of protein lysate, with a correlation coecient of 0.93.
To determine the optimum amount of monoclonal Raf-1 antibody for a given amount of protein lysate, increasing amounts of antibody were used to immunoprecipitate Raf-1 from SCF-stimulated H526 cells. The degree of MEK phosphorylation increased with increasing amounts of anti-Raf-1 antibody. Saturation for both Raf-1 and phospho-MEK detection was achieved between 1 and 2 mg of antibody for the 500 mg of protein lysate used in the immunoprecipitation step (Figure 3) , indicating that the amount of Raf-1 in the lysate was limiting at this antibody concentration. These data not only de®ne the optimum antibody concentration, but also again illustrate this assay is highly sensitive to the amount of input Raf-1 protein.
Paclitaxel is an anti-microtubule drug with signi®-cant clinical activity against a variety of tumors (Manredi and Horwitz, 1984; Rowinsky et al., 1988) . Intracellulary, paclitaxel induces microtubule bundling associated with a marked increase in the percentage of cells in the G2-M phase of the cell cycle, and this is followed by the DNA fragmentation and morphological features of apoptosis (Bhalla et al., 1993) . Blagosklonny et al. (1995) reported that these events were associated with paclitaxel-induced Raf-1 activation. To determine whether our assay could Figure 1 Kinetics of recombinant MEK-1 phosphorylation in vitro: (a) H526 cells were serum-starved overnight and stimulated with 100 ng/ml SCF for 5 min. Raf-1 was immunoprecipitated from 500 mg of lysate protein using a monoclonal antibody. An in vitro kinase assay was performed using increasing incubation intervals. The samples were resolved by SDS ± PAGE and probed with a polyclonal phospho-MEK antibody. The blot was stripped and reprobed sequentially for Raf-1 and MEK, demonstrating that approximately equal amounts of Raf-1 were immunoprecipitated and equal amounts of recombinant MEK-1 substrate were added. (b) H526 cells were serum starved overnight and then treated with 100 ng/ml SCF for 5 min or left untreated. Raf-1 was immunoprecipitated from 500 mg of protein lysate with 2 mg sheep polyclonal anti-Raf-1 antibody. Sheep serum was used in the control immunoprecipitation. An in vitro kinase assay was performed using increasing amounts of recombinant MEK-1 substrate. The blot was probed for phospho-MEK and then probed for Raf-1 to show that equal amounts of Raf-1 were immunoprecipitated. It was also probed for MEK to illustrate the addition of increasing amounts of recombinant MEK-1 substrate Oncogene A novel Raf-1 kinase assay C Bondzi et al detect this activation, H526 and U937 human histiocytic lymphoma cell lines were treated with 250 nM paclitaxel for 16 h in serum and the Raf-1 kinase assay was performed. H526 cells were also stimulated with SCF to compare growth factor-induced Raf-1 activation to paclitaxel-induced activation. Figure 4 illustrates that the assay was able to detect paclitaxel-induced Raf-1 activation, even though it occurred to a much lesser degree than growth factor induced activation. Probing the blot for Raf-1, we did not detect an electrophoretic mobility shift due to hyperphosphorylation of Raf-1 reported by several investigators upon paclitaxel treatment (Blagosklonny et al., 1995; Torres and Horwitz, 1998) . However, this is in agreement with the ®ndings of Wartmann and Davis (1994) who reported that electrophoretic mobility shift is not required for Raf-1 kinase activation.
We have demonstrated the utility of an activationspeci®c MEK antibody for the assessment of Raf-1 kinase activity, and characterized the optimal assay conditions using lysates derived from H526 cells. MEK phosphorylation peaked by 10 min and was sustained for the remainder of the 30-min incubation period, suggesting that the optimal incubation time for this assay could be as short as 10 min. The optimal recombinant MEK substrate was found to be 400 ± 500 ng for 500 mg of lysate protein. Lysate protein and Raf-1 antibody titration experiments indicated that the assay was very sensitive and completely dependent on the amount of input Raf-1 protein. The degree of MEK phosphorylation linearly correlated with the amount of Raf-1 immunoprecipitated when the amount of recombinant MEK-1 substrate was not limiting. In addition, we successfully employed the use of both monoclonal and polyclonal anti-Raf-1 antibodies, respectively directed against the N-terminal and C-terminal domains of Raf-1 in the immunoprecipitation step. The assay was able to detect paclitaxelinduced as well as growth factor-induced Raf-1 activation. Because of its sensitivity, speci®city, and ease, we believe that this assay is a signi®cant improvement over existing techniques.
Materials and methods

Cell culture
The H526 SCLC and U937 human histiocytic lymphoma cell lines were grown in RPMI 1640 supplemented with 2 mM L-glutamine and 10% fetal bovine serum (Hyclone, Logan, UT, USA). When H526 cells were grown in the absence of serum, 0.1% BSA (Sigma, St Louis, MO, USA) was added to the medium. For SCF-mediated Raf-1 activation, H526 cells were serum-starved overnight and either left unstimulated or stimulated with 100 ng/ml SCF (Peprotech Inc. Rocky Hill, NJ, USA) for 5 min at 378C. Figure 2 Raf-1 protein titration: (a) H526 cells were serum starved overnight and stimulated with 100 ng/ml SCF for 5 min. Raf-1 was immunoprecipitated from increasing amounts of protein lysate using the monoclonal antibody. In the control reaction, no protein lysate was added to the sample. A kinase reaction was performed using 500 ng of recombinant MEK-1 substrate and the samples were resolved by SDS ± PAGE. The blot was probed for phospho-MEK, Raf-1 and MEK. MEK phosphorylation increased with increasing amount of protein lysate with a plateau reached between 800 mg and 1600 mg. (b) A two-dimensional densitometric evaluation of the Raf-1 and phospho-MEK bands was performed and plotted against the amount of lysate protein. There was a linear correlation between the amount of input Raf-1 protein and the degree of MEK phosphorylation up to 800 mg of lysate protein. Correlation coecient, r xy =0.93, (x=pMEK, y=Raf-1) Figure 3 Anti-Raf-1 titration: The indicated amounts of monoclonal anti-Raf-1 antibody were used to immunoprecipitate Raf-1 from 500 mg of protein lysate from SCF-treated H526 cells. The Raf-1 immunocomplex was then used in a kinase reaction using 500 ng of recombinant MEK-1 substrate. In the control reaction no anti-Raf-1 was added to the tube. The degree of MEK phosphorylation increased with increasing amounts of anti-Raf-1 antibody with saturation occurring between 1 and 2 mg Figure 4 Paclitaxel-mediated Raf-1 activation: H526 and U937 cells were treated with 250 nM paclitaxel in serum for 16 h. For comparison, H526 cells were stimulated with 100 ng/ml SCF for 5 min. Raf-1 was immunoprecipitated from 500 mg of protein lysate and kinase assays were performed with 500 ng MEK-1 substrate. The assay detected paclitaxel-induced Raf-1 activation, however no electrophoretic mobility shift was detected when the blot was probed for Raf-1
Raf-1 immunoprecipitation and kinase assays H526 and U937 cells were washed once in PBS after SCF or paclitaxel treatment and lysed in buer containing 20 mM Tris (pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10 mM NaF, 1 mM Na pyrophosphate, 100 mM b-glycerophosphate, 10 mg/ml aprotinin, 1 mM PMSF, 10% glycerol and 1% v/v TritonX-100 (Anborgh et al., 1999) . The lysate was cleared by centrifugation at 10 000 g for 10 min at 48C. Protein concentrations were determined using the BCA method (Pierce, Rockford, IL, USA). Five hundred mg of the lysate protein was then added to 2 mg monoclonal antiRaf-1 antibody directed against the amino-terminal domain (Transduction Laboratories, Lexington, KY, USA) or 2 mg sheep polyclonal anti-Raf-1 antibody directed against the carboxy-terminal domain (UBI, Lake Placid, NY, USA). Antibodies were prebound to 100 ml of protein A+G-agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) by incubation for 1 h at 48C on a slow rotator. Where indicated, increasing amounts of lysate protein (0, 50, 100, 200, 400, 800 and 1600 mg) or increasing amounts of anti-Raf-1 antibody (0, 0.5, 1.0, 2.0 and 4.0 mg) were used in the immunoprecipitation step. Raf-1 was immunoprecipitated by incubation at 48C on a slow rotator for 2 h. The Raf-1 immunocomplex was washed three times in ice-cold lysis buer, once in icecold washing buer containing 10 mM HEPES (pH 7.4), 100 mM NaCl, 20 mg/ml aprotinin and 0.5% NP-40, and once in ice-cold reaction buer containing 20 mM Tris (pH 7.4), 20 mM NaCl, 1 mM DTT, 10 mM MgCl 2 , and 1 mM MnCl 2 . The kinase reaction was performed in the presence of 20 mM ATP and 500 ng of recombinant MEK-1 substrate (Santa Cruz Biotechnology), in a total volume of 40 ml of reaction buer at 308C for 30 min with gentle agitation. Where indicated, the kinase reaction was performed using increasing incubation intervals (0, 5, 10, 15, 20, 25 and 30 min) or increasing amounts of recombinant MEK-1 substrate (0, 100, 200, 400 and 500 ng). The kinase reaction was terminated by the addition of 40 ml 26SDS sample buer followed by boiling for 10 min. The samples were resolved by SDS ± PAGE, transferred to Immobilon-P membrane (Millipore Corp., Bedford, MA, USA) and probed with a polyclonal phospho-MEK antibody (New England Biolabs, Beverly, MA, USA). The blot was stripped and reprobed sequentially for Raf-1 and MEK with polyclonal anti-Raf-1 antibody (Santa Cruz Biotechnology), and monoclonal anti-MEK-1 antibody (Transduction Labs) respectively. Detection was accomplished using the ECL-Plus chemiluminescent system (Amersham, Arlington Heights, IL, USA) and visualized using a Fuji cooled CCD camera and the Aida 2.0 software package (Raytest Inc., New Castle, DE, USA).
Densitometric analysis
A two-dimensional densitometric evaluation of the Raf-1 and phospho-MEK bands was performed using the Aida 2.0 software package (Raytest Inc.).
